

References

-Abdel-Wahab, Z., W'eltz, C., Hester, D., Pickett, N., Vervaert, C and Seigler H. F. (1997) A phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells. Cancer 80: 401-412.

-Adams, M. D., S. E. Celniker, R. A. Holt, C. A. Evans, and J. D. Gocayne et al, (2000) The genome sequence of Drosophila melanogaster. Science 287:2185-2195.

-Akii, S., Caillaud, C., Vigne, E., Stratford-Perricaudet, L. D., Poenaru, L. and Perricaudet, M. (1996) Transfer of a foreign gene into the brain using adenovirus vectors. Nature Genetics 3:224-228.

-Albert DA. (1997) Genetics and molecular biology of Huntington's disease. TINS 18:11-14.

-Anderson DW, Ellenberg JH, Leventhal CM, et al. (1992) Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol 31:333-336.

-Anderson, W.F., (1992) Human Gene Therapy Science, vol 256 pp 808-813.

-Anderson, W. F. (1995) Gene therapy. Scientific American, pp. 124- 128.

-Anderson, W.F. (1998) Human gene therapy. Nature 392 (Supp.): 25- 30, 1998.

- Andreansky, S. S., Sorcoceanu, L., Flotte, E. R., Chou, J., Markert, J. M., Gillespie, G. Y., et al. (1997)** Evaluation of genetically engineered herpes simplex virus as Oncolytic agents for human malignant brain tumors. *Cancer Research* 57: 1502-1509.
- Annales Nestle. (1996). Strategy** for human genome project; 54:1-14.
- Annual meeting of American Academy of Neurology (April 2004).**
- Antinheimo J, Sankila R, Carpen O, Pukkala E, Sainio M and Jaaskelainen J.(2000)** Population based analysis of sporadic and NF2-associated meningiomas and schwannomas. *J Neurol* 54:71-76.
- Ascherio A, Bermudez CS, Garcia D, (1992)** Outbreak of buckthorn paralysis in Nicaragua. *J Trop Pediatr* ; 38(2); 87-9.
- Auburger G, Ratzlaff T, Lunkes A, Nelles HW, Leube B, Binkofski F, et al.(1996)** A gene for autosomal dominant paroxysmal choreoathetosis/spasticity (CSE) maps to the vicinity of a potassium channel gene cluster on chromosome 1p, probably within 2 cM between D1S443 and D1S197. *Genomics* 31:90-4.
- Austin FC. (1995)** Cancer immunology: highlights of the NCI extramural immunology program. *Cancer Invest* 8:207-28.
- Bajochi, G., Feldman, S. H., Crystal, R. G., and Mastrangeli, A. (1996)** Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors. *Nature Genetics* 3:229-234.

- Bankiewicz KS, Leff SE, Nagy D ,et al.(1997)** Practical aspects of the development of ex vivo and in vivo gene therapy for Parkinson disease. *Exp Neurol* 144:147-156 .
- Bardoni, A.; Felisari, G.; Sironi, M.; et al. (2000)** Loss of Dpl40 regulatory sequences are associated with cognitive impairment in dystrophinopathies. *Neuromuscul. Disord*: 10(3): 194- 199.
- Barohn, R.J. (2003)** Muscular dystrophies. In Goldman, L. and Bennett, J.C. (eds.): *Cecil Textbook of Medicine*. 21sted. W.B. Saunders Co.; PP. 2206-2210.
- Baser ME, Friedman JM, Aeschliman D, Joe H, Wallace AJ, Ramsden RT and Evans DG (2002)** Predictors of the risk of mortality in neurofibromatosis2. *Am J Hum Genet* 71:715-13.
- Bayertz K, Paslack R and Schmidt KW. (1999)** Summary of gene transfer into human somatic cells. State of the technology, medical risks, social and ethical problems: a report. *Hum Gene Ther* 5:465-468.
- Bayever E. Iversen PL Bishop M R .et al. (1999)** systemic administration of a phosphothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukaemia and myelodysplastic syndrome. *Antisense Res Dev*: 3:383-390.
- Beal MF, Hyman BT and Koroshetz W. (1993)** Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? *TINS* 16:125-31.

-Becker LE, Giangaspero F, Rorke LB et al. (2000) World Health Organization Classification of Tumors, Pathology and Genetics of Tumors of the Nervous System. Lyon, France: IARC Press, 123-148.

-Beesley, C.E., Meaney, C.A., Greenland, G., Adams, V., Vellodi, A., Young, E.P. and Winchester, B.G.(2001) Mutational analysis of 85 Mucopolysaccharidosis type I families: frequency of known mutations, identification of 17 novel mutations and in vitro expression of missense mutations. Hum. Genet. 109,503-511.

-Benamer HT, Patterson J, Wyper D.I, Hadley DM, Macphce G.I A and Grosset DG. (2000). Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 15:692-698.

-Betto, R.; Biral, D. and Sandona, D. (1999): Functional roles of dystrophin and of associated proteins. New insights for the sarcoglycans. Ital. J. Neurol.Sci.; 20 (6):371-379.

-Beutler E, Grabowski GA. Gaucher's disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, et al. (2004) the metabolic and molecular basis of inherited disease. 8th ed. USA: McGraw? 11, 2001:3635-68.

-Bilang-Bleuel A,Revah F, Colin P ,et al.(1997) Interstitial injection of adeno viral vector expressing glial cell line derived neurotrophic factor prevent dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson diseases. Proc Nati Acad Sci USA 4:8818-8823.

- Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C, Horn, S., Muna M., et al. (1996)** an adenovirus mutant that replicates selectively in p53-deficient human tumor cells. *Science* 274, 373-376.
- Blaese RM and Anderson WF (1992)** The ADA human gene therapy clinical protocol. *Hum Gene Ther* 1:327-362.
- Blaese RM, Culver KVV, Miller D, Carter CS, Fleisher T, et al.(1995)** T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. *Science* 270:475-80.
- Blmer, LI., Naldini, L., Kafri, T., Trono, D., Verma, I. M. and Gage, F. H. (1997)** highly efficient and sustained gene transfer in adult neurones with a lentivirus vector. *Journal of Virology* 71: 6641-6649.
- Boczkowski, J., Lanone, S., and Aubier, M. (2000)** Special characteristics of the diaphragm muscle cell. *Rev Mat Respn*: 17,569-573.
- Bordipion C, Mavilio F .Ferrari G ., et al. (1999)** Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocyte for the treatment of patient affected by ADA- deficient SCID *Hum Gene ther* 4:513-20 .
- Braak H. (2003)** neuropathological staging of AD. *Acta Neuropathol (Berl)*;82:239-259.
- Braak H, Braak E. (2000)** Pathoanatomy of Parkinson's disease. *J Neurol* 247 Suppl. 2:3-10:

-Britta Wahren (1999) Immunogenetic properties of genes. *Arm Oncologica*, Vol 38, no3, pp 309-311.

-Budker V, Gurevich V, Hagstom JE, Bortzov F and Wolff JA (1996) pH-sensitive, cationic liposomes a new synthetic virus-like vector. *Nat Biotechnol* 14:760-764.

-Byrnes A P, Rusby J E, Wood M J A and Charlton H M (1995) Adenovirus of gene transfer causes inflammation in the brain. *Neuroscience* 66:1015-1024.

-Camirand, G.; Caron, N.J.; Turgeon, N.A.; et al. (2006) Treatment with anti-CD 154 antibody and donor-specific transfusion prevents acute rejection of myoblast transplantation. *Transplantation*; 73 (3): 453-461.

-Canella B, Hoban C J, Gao Y L, et al. (2003) The neuregulin , glial growth factor 2, diminishes autoimmune demyelination and enhance remyelination in a chronic relapsing model for multiple sclerosis. *Proc Natl Acad Sci USA* 95:10100-10105.

-Caplan AL.(1992:) If gene therapy is the cure, what is the disease? In: Annas GJ, Elias S, editors. *Gene mapping: using law and ethics as guides*. Oxford, UK: Oxford University Press, 8:370-84.

-Caplen NJ ,Alton EW, Middleron PG ,et al. (1995) Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibroblast. *Nature Med* 1:39-45.

-Cao L, Zheng ZC, Zhao YC, et al. (1995) Gene therapy of Parkinson diseases model rat by direct injection of plasmid DNA-lipofectin complex. Hum Gene Ther 6:1497-150.

-Cao L, Ju DW, Tao Q, Wang J, Wan T and Wang M. (1998) Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitumor response in tumor-bearing mice. Therapy S, 1130-1136.

-Carlson, CG. (1998): The dystrophinopathies : an alternative to the structural hypothesis. Neurobiol. Dis.; 5 (1): 3 - 15.

-Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, et al. (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288: 669-672.

-Chang, AG and Wu, GY (1994) Gene therapy: applications to the treatment of gastrointestinal and liver diseases Gastroenterology 106:1076-1084.

-Cedazo-Minguez A, Popescu BO, Blanco-Millan JM, et al., (2003) Apolipoprotein E and beta-amyloid regulation of synapse kinase-3beta. J Neurochem 87:1152-1164.

-Channon KM and George SE (1997) Improved adenoviral vectors: cautious optimism for gene therapy. QJM 90:105 -109.

-Chauhan NB, Siegel GJ (2004) Immunization with anti-beta antibody. J Neurosci Res ; 74:142-147.

- Chen H, Mack LM, Kelly R, Ontell M, Kochanek S, and Clemens PR. (1999)** Persistence in muscle of an adenoviral vector that lacks all viral genes. *Proceedings of the National Academy of Sciences of the U.S.A.* 94: 1645-1650.
- Chiba A, Kusunoki S and Obata H. (1997)** Serum anti-GOI antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome: clinical and immunohistochemical studies. *Neurology* Oct; 43(10): 1911-7.
- Chiocca EA, Chio BB, Cai VV, DeLuca NA, Schaffer PA and Martuza FL. (1990)** Transfer and expression of the lacZ gene in rat brain neurons mediated by herpes symplex vims mutants. *New Biologist.* 2:739- 746.
- Christen Y. (2000)** oxidative stress and Alzheimer disease. *Am. J. Clin Nutr.* 71(2):621S-629S.
- Cirilli C, Inyaku K, Capogrossi MC, Yuan X and Williams JA.(1999)** Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma. *Journal of Neurooncology;* 43:99-108.
- Clemens PR. and Caskey CT. (1994)** Gene therapy prospects for Duchenne muscular dystrophy. *Eur. Neurol.;* 34: 181 - 185.
- Cluver JM. (2004).** Common pathologic mechanism of neurodegenerative diseases.

-Compton KJ. (2000) Gene transfer and synthesis of human factor IX in mice. *Gene* 161:123-130.

-Constantini LC, Bakowska JC, Breakfield X O and Isacson O (2000) Gene therapy in the CNS. *Gene ther* 7:93-109.

-Contassot E, Ferrand C, Certoux J, Reynolds C W and Tiberghien P. (1988) Retrovirus-mediated transfer of the herpes simplex type I thymidine kinase gene in alloreactive Tlymphocytes. *Human Gene Therapy* 9: 73-80.

-Cordier L, Gao G P, Hack A A. et al. (2005) Muscle specific promoters may be necessary for adeno-associated virus- mediated gene transfer in the treatment of muscular dystrophies. *Hum. Gene Ther.*; 12 (2): 205 - 215.

-Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, et al. (2006) A novel treatment of Gaucher's disease. *Lancet* 355: 1481-1495.

-Clrake A, Zeiler J, Rostaing-Rigattieri S, Brugieres P, Degos JD, Revuz J, et al. (2005) Neurological complications and management of mucopolysachardosis. *Brain* 122: 473-81.

-Crisby M, Carlson LA and Winblad B. (2002) Statins in the prevention and treatment of Alzheimer disease. *Alzheimer Dis AssocDisord* 16: 131-136.

-Croxford J L, Triantaphyllopoulos K, Podhacer O L, et al. (2003) Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system. *J Immunol* 160:5181-5187.

-Crystal, R G (2000) In vivo and ex vivo gene therapy strategies to treat tumors using adenovirus gene transfer vectors. *Cancer Chemotherapy and Pharmacology* 43; S90-S99.

-Culver K W, Anderson WF and Blease RM. (1991) Lymphocyte gene therapy. *Hum Gene Ther* 2:107-9.

-Cummings J L.(2001) Treatment of Alzheimer's disease. *Clin. Cornerstone* 3 (4): 27-39.

-Curie DT, Pilewski JM and Albelda SM (1996) Gene therapy approaches for inherited and acquired lung diseases. *Am J Respir Cell Mol Biol* 14:213-219.

-Czyzewski K, Lalowski M.M., Pfeffer A.and Barcikowska M. (2001) Lipid metabolism parameters in patients with Alzheimer's disease and their first degree relatives. *Acta Neurobiol Exp* 61: 21-26.

-Danko I & Wolff JA (1997) Direct gene transfer into muscle. *Vaccine* 12:1499-1502.

-Davis FG, Kupelian V, Freels S, McCarthy. Vaccination of malignant glioma patients with dendritic cells. *Cancer Res*; 34:56.

-DeAngles LM. Medical progress: brain tumors. N Engl Med; 114:213.

-De Silva S, Drachman D B, Mellitus D, et al., (1987) Prednisolone treatment in Duchenne muscular dystrophy. Arch. Neurol.; 44: 818-822.

-Desnick, R.J., Ioannou, Y.A. and Eng, C. (1995) alpha-galactosidase A deficiency: Fabry disease. In The Metabolic and Molecular Bases of inherited Diseases (vol. 2) pp. 2741-2784.

-De Wachter MAM. (1993) Ethical aspects of human germ-line gene therapy. Bioethics7:166-177.

-Diederich N and Goetz CG.(2000) Neuropsychological and behavioral aspects of transplants in Parkinson's disease and -- Huntington's disease. Brain Cogmt42:294-306.

-Doering LC. (1994) Nervous system modification by transplants and gene transfer. Bioassays 16:825-831.

-Drobyski WR, Knox KK, Majewski D, et al. (1994) Brief report: fatal, encephalitis due to variant B human herpesvirus-6 infection in a bone marrow-transplant recipient. New Engi J Med 330:1356-1360.

-Dubensky TW, Campbell BA and Villan LP et al. (1998) Direct transfection of viral and plasmid DNA into the liver and spleen of mice. Proc Nati Acad Sci USA 81:7529-7533.

- Duggan HY (2006)** Development of anti-tumor immunity. *Oncogenes* 14; 2005-2013.
- Dunham, K., (1999)** genetics as a major etiology in many human diseases; 121-123.
- Dunckley MG and Piper TA. (1995)** toward a gene therapy for Duchenne muscular dystrophy. *MRDD Research Reviews*. 1:71-78.
- During M J, Naegele J R, OMalley K and Geller A I. (1994)** Long-term behavioral recovery in Parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. *Science* 266: 1399-1403.
- Ebers GC, Yee IM, Sadovnick AD et al. (2000)** Multiple sclerosis: population-based prevalence and recurrence risks. *Ann Neuro* 148:927-931.
- Emerich DF, Winn SR, Hantraye PM, Peschanski M, Clien EV, Chu Y, et al. (2003)** Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. *Nature* 386:395-9.
- Eng CM, Guffon N, Germain DP, Lee P, Waldek S, et al. (2004)** Safety and efficacy of recombinant human α -galactosidase A replacement in Fabry's disease. *Mod* 345:9-16.
- Enquete Commission (1988)** A report from Germany an extract from the prospects and risks of gene technology: the report of the Enquete commission to the Bundestag of the Federal Republic of Germany. *Bioethics* 2:254-263.

-Eraser U. (1999) Human germ line gene therapy protocol. Hum Gene Therapy. 7; 2398-2400.

-Evans DGR, Huson SM, Donnai D, Neahy W, Blair V, Newton V and Harris R. (1998) A clinical study of type 2 neurofibromatosis QJMed 84:603-618.

-Evans DGR, Huson SM, Donnai D, Neary V, Blair V, and Newton V. (1992) A genetic study of type 2 neurofibromatosis in the United Kingdom I. Prevalence, mutation rate. Fitness and confirmation of maternal transmission effect on severity. Med Genet 29:841-846.

-Evans DGR, Lye R, Black G, Strachan T and Ramsden RT.(1999) The probability of bilateral disease in individuals presenting with a unilateral vestibular schwannomas J Neurol Neurosurg Psychiatry 6:764-767.

-Fan D S, Ogaawa M, Fujimoto K I, et al. (2005) Behavioral recovery in 6-hydroxy-dopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase gene using two separate adeno-associated virus vectors .Hum Gene Ther 9:2527-2535.

-Fang B, Eisensmith R C, and Woo S C. (2003) Phenylketonuria. A model for hepatic gene therapy. MRDD Research K; 1:56-61.

-Fassbender K, Stroick M, Bertsch T, Ragoeschke A, Walter S,et al.(2002) Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology 59:1257-1258.

-Fearon ER, Pardoll DM, Levitsky HI, Baker M, et al. (1998) Interleukin-2 production by tumor cells bypasses T-helper cell function in the generation of antitumor response. *Science* 254:713-6.

-Federico M (1999) Lentiviruses as gene delivery vectors. *Curr Opin Biotechnol* 10:448-453.

-Federoff J, Geschwind M D, Geller I. and Kessler J A. (1997). Expression of nerve factor in vivo from a defective herpes simplex virus 1 vector prevents effects of axotomy on sympathetic ganglia. *Proceedings of the National Academy of Sciences USA* 89: 1636-1640.

-Felgner P, Gadek TR, Roman R and Danielson M (1987) Lipofection: A highly efficient, lipid mediated DNA; transfection procedure. *Proc Natl Acad Sci USA* 84:7413-7417.

-Fenichel G, Pestronk A, Florence J, et al. (1997) A beneficial effect of oxandrolone in the treatment of Duchenne muscular dystrophy: A pilot study. *Neurology*; 48: 1225.

-Ferkol T, Perales JC, Mularo F and Hanson R. (1996) Receptor-mediated gene transfer into macrophages. *Proc Natl Acad Sci USA* - 93:101-105.200

-Ferry N, Duplessis O, Houssin D, Danos O, and Heard J. (1999) Retroviral mediated gene transfer into hepatocytes in vivo *Proceedings of the National Academy of Sciences USA* 8377-8381.

-Finsterer J, Stollberger C, Blazek G and Spahits E. (2001) Cardiac involvement in myotonic dystrophy, Becker muscular dystrophy and mitochondrial myopathy: a five-year follow-up Can. J. Cardiol.; 17 (10): 1061 - 1069.

-Fisher KJ, Kelley WM, Burda JF and Wilson JM. (1996) A novel adenovims-adenovirus-associated virus hybrid vector displays efficient rescue and delivery of the AAV genome. Human Gene Therapy 7: 2079-2087.

-Fleischman RA. (1995). South western internal medicine conference human gene therapy. American Journal of Medical Science 301:353-363.

-Fletcher JC. (2000) Hum Gene Ther 7(13): 1605.

-Fletcher JC and Anderson WF.(1992) Germ-line gene therapy: a new stage of debate. Law, Medicine and Health Care 20(1-2): 26-39.

Folstein SE, Leigh RJ, Parhad IM and Folstein MF (1986) The diagnosis of Huntington's disease. Neurology 36:1279-83.

-Fraser FC. (1993) Preimplantation diagnosis. In: Research volumes of Royal Commission on new reproductive technologies (vol 14). 743-752.

-Freelove AC and Zheng R. (2005) the power of ribozyme technologies: the logical way ahead for molecular medicine and gene therapy? Cur. Opin. Mol Ther. 4:419-22.

-French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. (1987) Efficiency of plasma exchange in Guillain-Barre syndrome: role of replacement fluids. *Ann Neurol* (6): 753-61,

-Friedman JM. (1999) Epidemiology of neurofibromatosis type1. *Med Genet* 89:1-6.

-Friedmann T. (2002) Lesch-Nyhan disease as a model for central nervous system directed gene therapy. *MRI D Research Reviews*. 1:49-55.

-Gaby AR. (1997) Commentary: Multiple sclerosis. *Nutrition & Healing* 4:1-11.

-Gavazzan TY, Clavo ER and Seller M. (2006) Transgenic models of SCID. *Hum Mol Genet*; 6:1622-1624.

-Geller AI, During M J, Freese F and Omnlw k. (1995) An HSV-1 vector expressing tyrosine hydroxylase causes production and release of L-DOPA from cultured rat striatal cells. *Journal of Neurochemistry* 64: 487-496.

-Gerard RD and Collen D. (1997) Adenovirus gene therapy for hyperchole-sterolemia, thrombosis and restenosis. *Cardio-vascular Research* 35:451-458.

-Giese A, Westphal S, Maher M (2004) treatment of malignant glioma: a problems beyond the margins of resection. *J Cancer Clin Oncol* 2004; 127: 217-225.

-Gill DR, Southern KW, Mofford KA, Huang L, Sorgi F, et al. (2004) A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. *Gene Ther* 4:199-209.

-Glimm H, Kiem HP, Darovsky B, Wolf J, Diehl V and Kalle C. V. (1997) Efficient gene transfer in primitive CD34+/CD38^{lo} human bone marrow cells reselected after long term exposure to GALV-pseudotyped retroviral vector. *Hum. Gene Therapy* 8: 2079-2086.

-Glorioso JC, DeLuca NA and Fink DJ. (1995) Development and application of herpes simplex virus vectors for human gene therapy. *Annual Review of Microbiology* 49: 675-710.

-Goebel EA, Davidson BL, Graham SM and Kern JA. (2006) Tumor reduction in vivo after adenoviral mediated gene transfer of the herpes simplex virus thymidine kinase gene and ganciclovir treatment in human head and neck squamous cell carcinoma. *Head and Neck Surgery* 119, 331-336.

-Gosele S, Dithmar S, Holz FG and Volcker HE. (2000) late diagnosis of Morquio syndrome. Clinical histopathological findings in a rare mucopolysaccharidosis. *Klin Monatsbl Augenheilkd* (2):114-7.

-Goverman J, Mizrahi T, Hauben E and Shaked I. (2006) Neuroprotective autoimmunity: naturally occurring CD4⁺cd5⁺regulatory t-cells suppress the ability to withstand injury to the CNS. *Curr Drug Targets Inflamm Allergy*; 5:234

-Graham FL, Smiley J, Russell WL and Nairn R. (1997) Characterization of a human cell line transformation by DNA from adenovirus 5. *General Virology* 36: 59-72.

-Graham FL and Van Der Eb AJ (2001) A new technique for the assay of infectivity of human adenovirus DNA. *Virology* 52:456-467.

-Griggs RC. (2001) Muscle diseases. In Andreoli T.E.; Carpenter C.J.; Criggs R.C. and Loscaizo J.: *Cecil Essentials of Medicine*. 5thed. W.B. Saunders Co.; PP. 988 - 997.

-Grossman M, Rader D, Muller DW et al. (1995) Apilot study of ex vivo gene therapy for homozygous familial hypercholesterolemia. *Nature Med* 1:1184-54 204.

-Grossman M, Raper SE, Kozarsky K et al. (1994) Successful ex vivo gene therapy directed to liver in patient with familial hypercholesterolemia. *Nature Med* 6:335-41.

-Guillamo JS, Monjour A, Taillandier L, Devaux B, Varlet P et al. (2001) Brainstem gliomas in adults: prognostic factors and classification. *Brain* 124: 2528-39.

Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, et al. (1997) The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and 2. *JAMA* 278:51-7.

- Guy J, Qi X and Hauswirth WW (1998)** Adeno-associated viral mediated catalase expression suppresses optic neuritis in experimental allergic encephalomyelitis .Proc Nat Acad Sci USA 95:13847-13852.
- Hahn A F. (1998)** Guillain Barre Syndrome. Lancet 352:635-641 .
- Hall WA, Wang M and Rahman A. (2004)** Telomerase as therapeutic target for malignant gliomas. Oncogene 21:631-643
- Hao S, Huang TG, Savontus MJ, et al. (2005)** Gene therapy for chronic pains
- Haque N and Isacson O. (1997)** Antisense gene therapy for neurodegenerative disease. Exp Neurol 144:139-46.
- Harper PS and Clarke A. (1990)** should we test children for "adult" genetic diseases. Proceedings of the National Academy of Sciences of the U.S.A. 94: 5804-5809.
- Harper SQ, Hauser MA, Dellorusso C, et al. (2006)** Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med.; 8 (3): 253 - 261.
- Harris JD and Lemoine NR. (1996)** Strategies for targeted gene therapy. Trends in Genetics 12: 400-404.
- Hartigan-O'Connor D. and Chamberlain JS. (2003)** Developments in gene therapy for muscular dystrophy. Microsc. Res. Tech.; 48: 223 - 238.

-Hauser AC, Lorenz M and Sunder-Plassmann G. (2004) the expanding clinical spectrum of Anderson-Fabry disease: a challenge to diagnosis in the novel era of enzyme replacement therapy. Intern Med Jun; 255(6): 629-36.

-Helene UJ (1999). Better Health through Gene Therapy. The futurist 32; 39-42.

-Herman WT. and Verhaagen J. (1998) Viral vectors, tools for gene transfer in nervous system. Progress in neurobiology 55, 399-434 206.

-Hilton-Jones D. (2001) Muscle diseases. In Donaghy, M. (ed.): Brain's Diseases of the Nervous System. 11th ed. Oxford University Press; PP. 461-506.

-Hock C, Konietzko U, Papassotiropoulos A, et al. (2005) generations of antibodies specific for beta-amyloid by vaccination of patients with AD. Nat Med; 8:1270-1275

-Hogan SP, Foster PS, Tan X and Ramsay AJ. (1998) Mucosal 1L-12 gene deliveries inhibits allergic airways disease. J Immunol 28:413-423.

-Hohlffeld R. (2006) current gene therapy of multiple sclerosis; 62:125

-Holland FC. Glioblastoma multiforme: the terminstor. Proc Natl Acad Sci USA 2003; 79: 235-245.

-Hong S S, Karayan L, Tournier J and Curiel DT. (1997). Adenovirus type 5 fiber knob binds to MHC class Ia2 domain at the surface of human epithelial and 13 lymphoblastoid cells. EMBO Journal 16: 2294-2306.

-Horrelou P, Vigne E, Castel M, et al (1999) direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease. Nat. Med. 5:881-889.

-Huang E, Teh BS, Strother DR et al. (2002) Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity, Int J Radiat Oncol Biol 52:599-605 .

-Huang EJ, Vee HK, Shew JY, Friedman T and Lee WH. (1998) Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 242:1563-1566.

-Huang V, Alexander GE, et al. (1999) High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: MRS study. Am. J. Psychiatry 156(12): 1879-86..

-Huard J, Roy R, Guerette B, et al. (1999) Human myoblast transplantation in immunodeficient and immunosuppressed mice: evidence of rejection. Muscle Nerve; 17: 224 - 234.

-Hull MS, Stauss S, et al. (1996) inflammatory mechanisms in Alzheimer's disease. Eur. Arch. Psychiatry Clin. Neurosci 246(3): 124-8.

-Imai E, Akagi Y and Isaka V. (2006) towards gene therapy for renal diseases. *Nephrol* 19: 397-402.

-Imai E and Isaka Y (2006) Strategies of gene transfer for the kidney *Kidney Int* 53:264-272.

-Jaffe KM, McDonald CM, Ingman E. and Haas J. (1990): Symptoms of upper gastrointestinal dysfunction in Duchenne muscular dystrophy case control study. *Arch. Phys. Mod Rehabil.*; 71: 742-744.

-James N and Sikora K. (1993) Tumour-associated antigens. *Clinical immunology*. 4th ed. Oxford: Blackwell Scientific 1773-84.

-James N, Edwards S, Hui KM, and Grosveld F. (1991) the effect of class II gene transfection on the tumorigenicity of the H-2K.-negative mouse leukemia cell line K 36.16. *Immunology* 72:213-8.

-Jelic V. and Winblad B. (2003) Treatment strategies in Alzheimer Disease. *Brain Aging* 2: 20-23.

-Jenkins RG, Herrick SE, Meng GH, et al. (2000) an integrin-targeted non-viral vector for pulmonary gene therapy. *Gene Ther* 7:393- 400.

-Jobin C, Panja A, Hellerbrand C, Limuro Y, and Sartor R B. (1998) Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor kB super-repressor in human intestinal epithelial cells. *The Journal of Immunology* 160: 410-418.

-Johnson PA, Miyanohara A, Levine F. and Friedman T. (1992) Cytotoxicity of a replication-defective mutant of herpes simplex virus type I. *Journal of Virology* 66:2952-2965.

-Joss K, Yang Y. and Wilson JM. (1996) Cyclophosphamide diminishes inflammation and prolongs expression follow up; delivery of adenoviral vectors to mouse liver and lung. *Human Gene Therapy* 7: 1555-1566.

-Jorgensen C, Demoly P, Noel D, Bousquet J and Sany J. (1997) Gene transfer to human rheumatoid synovial tissue engrafted in SCID mice. *Rheumatol* 24:2076-2079.

-Juengst Eric T. (1999) The NIH "Points to Consider" and the Limits of Human Gene Therapy. *Human Gene Therapy* 1(4): 425-433.

-Kafri T, Elmer U, Peterson DA. and Verma IM. (1997) Sustained expression of genes delivered into liver and muscle by lentiviral vectors. *Nature Genetics* 17:314-317.

-Kay MA, Gloriso JK and Naldini L (2001): Gene transfer into recipient cell. *Nat Med*; 7:33-70.

-Kay MA, Meuse L, Gown AM, Aruffo A. and Wilson C B. (1997) Transient immunomodulation with anti-CD40 ligand and CTLA41g enhances persistence and secondary adenovirus-mediated gene. *Proceedings of the National Academy of Sciences of the U.S.A.* 94:4686-4691.

-Kennedy P E. (1997). Potential uses of herpes simplex virus (HSV) vectors for gene therapy of neurological disorders. *Brain* 120: 1245-1259.

-Khan TA, Selike FW, and Laham RJ. (2005) Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia. *Gene Ther.* 10:285-291.

-Kim SH, Yu S, Park JS, Robbins PD, and Kim S. (1999). Construction of retroviral vectors with improved safety. Gene expression. *Journal of Virology* 72: 994- 1004.

-Kim S, Lin H, Barr E, Leiden JM. And Parmacek MS. (1998). Transcriptional targeting of replication-defective adenovirus transgene expression to smooth muscle cells in vivo. *Journal of Clinical Investigation* 100: 1006-1014.

-Kirsteins AE. And Kolaski K. (2000) Neuromuscular diseases In Grabois: *Physical Medicine and Rehabilitation: the complete Approach*. 1sted, Baylor College of Medicine, Houston, Texas PP. 1624-1674.

-Klein RL, Muir D, King MA, et al. (1999) Long-term action of vector- derived nerve growth factor or brain derived neurotrophic factor choline acetyltransferase *Neuroscience* 90.815-821.

-Kluwe L, Mautner V, Heinrich B, Friedrich RE and MacCollin M (2003) Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. *J Med Genet* 40:109-14.

-Knox KK, Brewer JH, Henry JM, et al.(2000) Human herpes virus 6 and multiple sclerosis: systemic active infections in patients with early disease. Clin Infect Dis 31:894-903.

-Kohl DB, Hershfield MS, Carbonaro D, Smogorzewska EM, et al. (1998) T-lymphocytes within normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat Med 4: 775-780.

-Kondziolka D, Lunsford LD, McLaughlin MR and Flickinger JC.(1998) Long-term outcomes after radio surgery for acoustic neuroma. N Engl J med 339:1426-1433.

-Koransky ML, Robbins RC: and Blau HM. (2006) VEGF gene delivery for treatment of ischemic cardiovascular disease. Trends Cardiovasc Med. 12:108-114.

-Kotin RM, Siniscaico M, Hunter L, Laughlin CA, et al. (1999) Site-specific integration by adeno-associated virus. Proceedings of the National Academy of Sciences of the U.S. Ass. 87: 2211-2215.

-Kremer B, Goldberg P, Andrew SE, Tlieilmann J, Telenius H, Zeisler J, Squitieri F, et al (1994) A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. N Engi J Med 330:1401-6.

-Kucharizuk JC, Randazzo B, Amin KM Elshami A, et al. (1997) Use of a replication-restricted herpes virus to treat experimental human malignant mesothelioma. Cancer Research 57: 466-471.

-Laitinen M, Miikinen K, Manninen H, Kossila M, Agrawal RS, et al. (2006) Adenovirus-mediated gene transfer to limb artery of patients with chronic critical leg ischemia. *Hum Gene Ther* 9:1481-1486.

-Landtblom AM, Flodin U, Karlsson M, et al. (1993) Multiple sclerosis and exposure to solvents, ionizing radiation, and animals. *Scand J Work Environ Health* 19:399-404.

-Latchman DS. (1994) Germline gene therapy. *Gene Therapy* 1(5): 277-279.

-Lee SS, Eisenlohr LC, McCue PA, Mastrangelo MJ and Lattime EC (1997) Intravesical gene therapy: in vivo gene transfer: recombinant vaccinia virus vectors. *Cancer Res* 54:3325-3328.

-Leff S E, Rendahl K G Spratt S K et al. (1998) In vivo L-dopa production by genetically modified primary rat fibroblast or glioblastoma cell grafts via coexpression of GTT cyclohydrolase 1 with tyrosine hydroxylase. *Exp Neurol* 151:249-264.

-Lehrman Sally. (1999) Virus Treatment Questioned After Gene Therapy Death. *Nature* 401(6753): 517-8.

-Leon SH, Schuffier MD, Kettler M. and Rohrman CA. (1986) Chronic intestinal pseudobstruction as a complication of Duchenne's muscular dystrophy. *Gastroenterology*; 90: 455 -459.

-Lewin MJ. (2000) Human genetics disorders: new aims and results; 112-117.

- Limdborg LF, Doherty D, Lile J, et al. (1998)** A cell lined-derived neurotrophic factor for the mid-brain dopaminergic neurone .Science 260:113-132.
- Li H, Alonso-Vanegas M, lung S, Sadikot, AF, et al. (1999)** Intracerebral adenovirus-mediated p53 tumor suppressor gene therapy for experimental human glioma. Clinical Cancer Researches, 637-642.
- Lisak RP. (1998)** Intravenous immunoglobulin in multiple sclerosis. Nairn 51:25-29.
- Line SH, Schilling G, Young W, Margolis RL, Wagster MV, et al.(1993)** Huntington's disease gene (IT15) is widely expressed in human and rat tissues. Neuron 1993: 11:985-93.
- Listernick R, Charrow J and Gutmann DH.(1999)** Intracranial gliomas in neurofibromatosis type 1. Am J Med Genet 89: 38-44.
- Listernick R, Darling C, Greenwald M, Strauss L and Charrow J.(1995)** Optic pathway tumors in children: the effect of NF1 on clinical manifestations and natural history. J Pediatr 127:718-22.
- Listernick R, Louis DN, Packer RJ and Gntmann DH. (1997)** Optic pathway gliomas in children with neurofibromatosis I: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 41:143-9.

-Losordo DW, Vale PR, Hendel RC, et al. (2005). Phase 1/2 placebo controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. *Circulation*. 105: 2012-2018.

-Lozier JN., Yankaskas JR, Ramsey WJ, and Morgan, RA. (1997). Gut epithelial cells as targets for gene therapy of hemophilia. *Human Gene Therapy* 8: 1481-1490.

-Luchsinger JA, Tang MX, Shea S. and Mayeux R. (2003) Antioxidant vitamin intake and risk of Alzheimer disease *Arch Neurol* 60: 203-208.

-Lyerly HK and DiMaio JM (1999) Gene delivery systems in surgery *ArchSurg* 128:1197-1206.

-Mac Collin M, Ramesh V, Jacoby LB, Louis DN, Rubio MP, Pulaski K, Trofatter JA, et al.(1994) Mutational analysis of patients with NF 2. *Am J Hum Genet* 55:314-320

-McLaren A. (1998) Problems of germ line therapy¹, *Nature*, 392: 645.

-Macmillan Publishers et al. (1999) *Nature Med.* Vol (2); 289-342

-Macmillan JC, Davies P and Harper PS (1995) Molecular diagnostic analysis for Huntington's disease: a prospective evaluation. *J Neurol Neurosurg Psychiatry* 58:496-8.

- Maeda Y, Ikeda U, Urabe M, Kurtzman G. and Ozawa K. (1997)** Gene transfer into vascular cells using adeno-associated virus (AAV) vectors Cardiovascular Research 35: 514-521.
- Maidment N T, Tan A M, Bloom D C, et al. (1996)** Expression of the lac Z receptor gene in the rat basal forebrain, hippocampus using non replicating herpes simplex vector. Exp Neurol 199 M07-1I4.
- Mandel R J, Gage F H, Clevenger D G et al. (1999)** Nerve growth factor expressed in the medial septum following in vivo gene delivery. Exp Neurol 155:59-64.
- Mandel R, Rendahl KG, Spratt SK, et al. (1998)** Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. Journal of Neuroscience, 12, 4271-4284.
- Mankodi A, Logigian E, Callahan L, et al. (2000)** Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 289, 1769-1773.
- Marcel T, Grausz JD. (2006)** The TMC worldwide gene therapy enrollment report. Hum Gene Ther 8:775-800.
- Marconi P, Krisky D, Oligino T, and Glorioso J C. (1999)** Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proceedings of the National Academy of Sciences USA 93: 11319-11320.

- Markowitz D, Goff S. and Bank A. (1998)** a safe packaging line for gene transfers: separating viral genes on two different plasmids. Journal of Virology 62: 1 120-1 124.
- Martin JB. (1999)** Molecular basis of the neurodegenerative disorder N. Engl. J. Med. 340(25): 1970-80.
- Martino G, Poliani P, Marconi C, Comi G, Furlan R, et al . (2005)** Cytokine gene therapy of autoimmune demyelination revisited using herpes simplex virus type-1 derived vectors. Gene Ther 1087-1093.
- McConkey. Boston: Jones and Bartlett Publishers (2000)** Treatment of Genetic Disease. Human Genetics: The Molecular Revolution Ed. W.H. 202-214.
- McDonald CM, Abresch RT, Carter GT, et al. (1995):** Profiles of neuromuscular diseases: Decker's muscular dystrophy. Am J. Phys. Med. Rehabil.; 74 (Suppl.): 93 - 103.
- McGaughran JM, Harris DI, Donnai D, Westerbeek R, et al.(1999)** A clinical study of type 1 neurofibromatosis in north west England. J Med Genet 36. 197-203.
- McGeer EG. And McGeer PL. (1999)** Brain inflammation in Alzheimer disease and the therapeutic implications. CHIT Pharmaceut. Design 5(10): 821 -36.
- Mckusick HJ. (1998)** Impacts of human genetics in all diseases incidence 3:243-249.

-McLare A. (1998) 'Problems of germ line therapy', Nature, 392: 645.

-Medin JA, Tudor M, Simovitch R, Quirk JM, and Brady RO (2001) Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector. Proc Natl Acad Sci USA 93:7917-7922.

-Mehta A. (2005) new developments in the management of Anderson-Fabry disease. 0.1 Med 95: 647-53.

-Meikle PJ and Hopwood J. (2000) Lysosomal storage disorders Prevalence and newborn screening. Gaudier Gin Perspect 8 -5.

-Miller AD (1996) Human gene therapy comes of age. Nature 357:455 460.

-Miller RG. and Hoffman EP. (1994) Molecular diagnosis and modern management of Duchenne muscular dystrophy. Neurol. Clin.; 12:699-725.

-Miller RG, Pavlath G, Sharma K, et al. (1999): Myoblast implantation in Duchenne muscular dystrophy: The San Francisco Study. Neurology; 42:189.

-Mincera A, Vigneti E. and Alois L. (1998) Change of NGF presence in non-neuronal cells in response to experimental allergic encephalomyelitis in Lewis rat. Exp Neurol 154:41-46.

-Minler-Brown HS. And Miller RG. (1988): Muscle strengthening through high-resistance weight training in patients with neuromuscular disorders. Arch. Phys. Med. Rehabil; 69: 14 -19.

-Mochizuki et al, PNAS. (2005) An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's Disease Vol. 19:10918-10923.

-Mohrenschlager M, Braun-Falco M, Ring J, Abeck D (2003) Fabry disease: recognition and management of cutaneous manifestations. Am J Clin Dermatol; 4(3): 189-96.

-Morgan D, Diamond DM, Gottschall PE, et al. (2004) A beta peptide vaccination prevents memory loss in animal models of AD. Nature; 408:982-985.

-Morral N, O'Neal WK, Leland MM, Piedra PA. And Langston C. (2002) Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum. Gene Ther; 13, 143-154.

-Moser HW. (2002) A role for gene therapy in mental retardation. MRDD Research Reviews. 1: 4-6.

-Moyhuddin A, Baser ME, Watson C, Purcell S and Evans DG. (2003) Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. J Med Genet 40:459-63.

-Mulligan RC (1999) the basic science of gene therapy. Science 260:926-932.

-Munch M, Hvas J, Christensen T, et al.(1997) The implications of Epstein-Barr virus in multiple sclerosis a review. Acta Neurol Scandl997; 169:59-64.

-Munsat TL. (1998) Review of neuromuscular diseases. Phys. Med Rehabil. 2:467-480.

-Murry M and Pizzorno JE. (1998) Multiple Sclerosis. In: Murray MT, Pizzorno IE; Encyclopedia of Natural Medicine. Rocklin. CA: Prima HeaJth: 666-676,900-901.

-Muzyczka N. (1992) Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells. Current Topics in Microbiology and Immunology 158:97-129.

-Nakai H, Montini E, Fuess S, Storm TA, Grompe M and Kay MA.(2005) AAV serotype 2 vectors preferentially integrate into active genes in mice. Nature Genet. 34,297-302.

-Naldini, L., Blomer, U., Galloway, P., Ory, D., Mulligan, R., Gage, F. H., Verma I. M. and Trono, D. (1996) In vivo gene delivery and stable transduction of non dividing cells by a lentiviral vector. Science 272: 263-267.

-Nelson, Deborah, Weiss and Rick.(1999) NIH Not Told of Deaths in Gene Studies. Washington Post November 3, 1999: A1, A6-A7.

-Nelson,M.R.(2004) Rehabilitation concerns in myopathies. In Braddom.: Physical Medicine and Rehabilitation. 2"ed. W.B. Saunders Co.; PP. 1045- 1072.

- Neufeld, E.F. (1991)** Lysosomal storage diseases. *Annu Rev Biochem* 60, 257-280.
- **Neumeyer,A.M.;Cros, D.;McKenna-Vasek, D.; et al. (1998)** Pilot study of myoblast transfer in the treatment of Becker muscular dystrophy. *Neurology*; 51(2): 589 - 592.
- Neuwelt, E. A., Rosenberg, W. G., (1994)** Characterization of a new model of GM2 gangliosidosis (Sandhoffs disease) in Korat cats. *Journal of Clinical Investigation* 76:482490.
- Nichols, E.K.,(2003)** *Human Gene Therapy* , Harvard University Press," Cambridge, Massachusetts PP 1-251.
- Nienhuis AW, McDonagh KT and Bodine DM. (1999)** Gene transfers into hemopoietic stem cells, *cancer* 67:2700-4.
- Nilaver, G., L. L. Muldoon, R. A. Kroll, M. A. Pagel, X. O. Breakefield, B. L. Davidson, and E. A. Neuwelt.(1995)** Delivery of herpesvials and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption. *Proc. Natl. Acad. Sci. USA* 92:9829-9833.
- Noseworthy JH(1999)** Progress in determining the causes and treatments of multiple sclerosis. *Nature* 399:A40-A47.
- Numes, F. A. and Raper, S. E. (1996)** Liver-directed gene therapy *Medical Clinics of North America* 80: 1201 -1213.

-Offen D, Sherki Y, Melamed E, et al.(2006) Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures relevance to neuroprotection in Parkinson's disease. Brain Res 854:257-262.

-Ogawa, N., Fujiwara, T., Kagavva, S., Nishizaki, M., Morimoto,Y, Tanida, T., et al. (1997) Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent International Journal of Cancer 73: 367-370.

-Oldfield, E. H. and Ram, Z. (1995) Intrathecal gene therapy for the treatment of leptomeningeal carcinomatosis. Human Gene Therapy 6: 55-85.

-Orel S. (1995) historical gene therapy. Human genetics 112-113.

-Packer RJ, Raffei C, Villablanca JG et al.(2003) Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J Neurosurg 92:249-254.

-Paillard, F. (1998) Suicide against brain tumors. Human Gene Therapy 9: 3-4.

-Parkman R (1996) the application of bone marrow transplantation to the treatment of genetic diseases. Science 232: 1373-1378

- Parry DM, MacCollin M, Kaiser-Kupfer MI, Nicholson HS, Bolesta M and Eld ridge R.(1996)** Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. *Am J Hum Genet* 59:529-539.
- Paster GM and Thadhani R. (2001)** Enzyme replacement therapy for Anderson-Fabry disease. *Lancet* 358: 601-3.
- Paul Smaglik,(1999)** Tighter watch urged on adenoviral vectors, *Nature*, Vol402,707.
- Perlmutter, D. Brain Recovery.com (2000)** Naples, FL: The Perlmutter Health Center.
- Peroutka SJ, Wilhoit Tand Jones K.(1997)**Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles. *Neurology* 49:201-6.
- Philip Noguchi,(2006)** Risks and Benefits of Gene Therapy Volume 348:193-194 .
- Piccolo, F., Moore, S.A., Mathews, K.D. and Campbell, K.P. (2005)** Limb-girdle muscular dystrophies. *Adv. Neuro/.*, 88, 273-291.
- Pizzorno, J.E.and Murray, M.T.(1995)** Alzheimer's Disease. *A Textbook of Natural Medicine* 74,530-65.
- Pollack IF and Mulvihill JJ.(1996)** Special issues in the management of gliomas in children with neurofibromatosis J. [Review], 28: 257-68.

-Pollack IF, Shultz B and Mulvihill J.J.(1996) The management of brainstem gliomas in patients with neurofibromatosis 1 *Neurology* 46: 1652-60.

-Pomeroy SL, Tamayo P , Gaasenbeek M et al. (2002) Prediction of central nervous system embryonic tumor outcome based on gene expression. *Nature* 415:436-442.

-Porteous DJ, Dorin JR, McLachlan G, Davidson-Smith H, Davidson H, Stevenson BJ, et al.(2004) Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. *Am J Hum Genet* 74:210-18.

-Prineas F, Lechanteur C, Lopez M ,et al(2000) Similar efficiency of DNA -liposome complexes and retrovirus-producing cell HSV-tk suicide gene therapy of peritoneal carcinogenesis .1 *Drug Target J* 8:79-89.

-Prins RM. (2005) Cancer immunology and immunotherapy; *Immunol Rev* 205:243

-Quellette H, (1999). Human gene therapy protocols; new aims *Hum Gene Ther* 10:22-27

-Rainov, N. G., C. Zimmer, M. Chase, C. M. Kramm, E. A. Chiocca, R. Weissleder, and X. O. Breakefield (1995) Selective uptake of viral and monocrySTALLine particles delivered intracranially to experimental brain neoplasms. *Hum. Gene Ther* 6:11.-1552.

-Rain, Z., Culver, K. W., Walbridge, S., Blaese, R. ML, and Oldfield, E. H. (1993) In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. *Cancer Research* 53:83-88.

-Ram, Z., K. W. Culver, E. M. Oshiro, J. J. Viola, H. L. DeV room. I. Otto, Z. Long, Y. et al. (1997) Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. *Nat. Mecl.* 3:1354-1361.

-Rascol O, Sieradzan K, Peyro-Saint-Paul H, et al. (1998) Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy. *Mov Disorl* 3:673-676.

-Rasmussen SA and Friedman JM. (2000) NF1 gene and neurofibromatosis 1. *Am J Epidemiol* 151: 33-40.

-Raymon H K, Those S and Gage Fh (1997) Application of ex vivo gene therapy in the treatment of parkinsons diseases. *Exp Neurol* 144:82-91.

-Reiss O, Kulm V and Krueger R. (2000) Genetic influence on the development of Parkinson's disease. *J Neurol* 247 Suppl 2:69- 74.

-Religa D., Styczynska M., Peplonska B., Gabryelewicz T., Pfeffer A., Chodakowska M., Stepien K., et al. (2003) Homocysteine, apolipoproteine E and methylenetetrahydrofolate reductase in Alzheimer's disease and mild cognitive impairment. *Dement GenatrCogn Disord* 16: 64-70.

-Ridet, J L., Corri, O., Pencalet, P., et al (2004) toward autologous ex vivo gene therapy for the central nervous system with human adult astrocytes. Human Gene Therapy, 20, 271-280.

-Rivire, I., Brose, K. and Mulligan, R. C. (1995). Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proceedings of the National Academy of Sciences of the U.S.A. 92: 6733-6737.

-Riviere M, Meininger V, Zeisser P, Munsat T.(1998) An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol 55:526-528.

-Rizzuto G, Oipelletti M , Maiione D, et al .(1999) Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation .Proc Nat. Acad Sci USA 96:64 IT- 6422 .

-Robertson EJ, et al. (1983) J Embryol Exp Morphol 74:297.

-Robinson, iVI.B., Batshaw, M.L., Ye, X. and Wilson, J.M. (1995) Prospects for gene therapy in Ornithine Carbamoyltransferase Deficiency and other urea cycle disorders. MRDD Research Reviews. 1:62-70,

-Roeleveld, N.,G. A. Zielhuis, and F. Gabreels,(1997) The prevalence of mental retardation: a critical review of recent literature. Dev. Med.Child Neurol.39:125-132.

-Rolinn de Silva HA, Khan NL and Wood NW.(2000) The genetics of Parkinson's disease. Curr Opin Gen Dev 10:292-298.

- Rols M P ,delteil cgozio m ,et al (1998)** in vivo electrically mediated protein and gene transfer in murine melanoms .-Nat Biotechnol 16:168-171 .
- Rome, J. J., Shayani, V., Newman, K. D., Farrell, S., Lee, S. VV., Virmani, R. and Dicheck, D. A. (2000).** Adenoviral vector mediated gene transfer into sheep arteries using a double- balloon catheter. Human Gene Therapy 5: 1249-1258.
- Rosenberg, R. N. (1984)** Molecular genetics, recombinant DNA techniques, and genetic neurological disease. Annals of Neurology 15:511-520.
- Rosenberg SA (1994).** Gene therapy for cancer. JAMA 268:246-9.
- Rosenfeld MA .Siegfried W Yoshimura K et al (1998)** Adenoviral-mediated transfer of recombinant alpha -1-antitrypsin gene to the lung epithelium in vivo. Science: 252:43M.
- Ross, G., Erickson, R., Knorr, R., iViotulsky, A. G., Parkman, R., Straus, S. E. and Smith, B. R. 1(2004)** Hum. Gene Ther. 7, 1781-1790 .
- Rossi JJ. (2001)**Therapeutic antisense and ribosome. Br Med Bull: 51:217-25.
- Ross RT, Cheang M, Landry G, et al.(1999)** Herpes zoster and multiple sclerosis. Can J Neurol Sci 26:29-32.

-Roth, J. A., Nguyen, D., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Person, D. Z., Hong, W. K., et al. (1996) Retrovirus mediated wild-type p53 gene transfer to tumors of patients with lung cancer. *Nature Medicine* 2: 985-991.

-Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, et al. (1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. *Nature* 363:515-521.

-Roy K. (2005). Medical progress in brain tumors treatment. *Nat Med*; 45:123

-Rubio, F. J., Bueno, C., Villa, A., et al (2000) genetically perpetuated human neural stem cells engraft and differentiate into the adult mammalian brain. *Molecular and Cell Neuroscience*, 16, 1-13.

-Rulifson, E. J., S. K. Kirn, and R. Nusse, (2002) Ablation of insulin-producing neurons in flies: growth and diabetic phenotypes *Science* 296: 1118-1120.

-Russell SJ. (1996) Lymphokine gene therapy for cancer. *Immunology Today*. 11:383-90.

-Russell and Stephen, J (2004) Goal of gene therapy is to treat and/or cure genetic diseases. *Journal* 315.7118 (1997): 1289+

- Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna W,J, et al.(2002)** Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. *Circulation* 105: 1407-11.
- Sarnat, H.B. (2005)** neuromuscular disorders. In Behnman, R.E.: KJiegman, R.M. and Jenson, H.B. (eds.): *Nelson Textbook of Pediatrics*. 16th ed. W.B. Saunders Co.: PP. 1867 - 1893.
- Safer RA and Rostami A: (1998)** Treatment of Gillian-Barre syndrome with intravenous immunoglobulin. *Neurology* (6 Suppl 5): S9- 15.
- Saunders CD.(2000).** Parkinson's disease: A New Hope. Boston, MA: Harvard Health Publications .vol.75:847-860.
- Sawtell, N. M. and Thompson, R. L. (1992)** Herpes simplex virus type 1 latency-associated transcription unit promotes anatomical site- dependant establishment and reactivation from latency. *Journal of Virology* 66: 2157-2169.
- Scheffler, B., Horn, M., Blumcke, L., et al (1999)** Marrow-mindedness: a perspective on neurogenesis. *Trends in Neuroscience*, 22, 34.S- 357.
- Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, VVeibel T, et al.(2005)** Enzyme replacement therapy in Fabry disease: a randomized controlled trial. *JAMA* 285: 2743-9.

- Schmid RM, VVeidenbach H, Yamagushi H, Liihrs H, Liptay S and Adier G (1998)** Direct gene transfer into the rat pancreas using DNA-liposomes. *Eur J Clin Inwst* 28:220-226.
- Scott, H.S., Bunge, S., Gal, A., Clarke, L.A., Morris, C.P. and Hopwood, J.J. (1999)** Molecular genetics of Mucopolysaccharidosis type I: diagnostic, clinical, and biological implication. *Hum. Mutat.* 6, 288-302.
- Schwartz M, Kipnis J, Marodon G (2005)** Autoimmunity on alret: naturally occurring regulatory CD4 (+) CD25 (+) T-cells as part of the evolutionary comprise between a need and a resk. *Trends Immunol*; 23:530.
- Selkoe D.J., (1999)** Translating cell biology into therapeutic advances in Alzheimer's disease. *Nature* 399 (suppi): A23-31.
- Shi N, Pa rd ridge W M (2000)** Noninvasive gene targeting to the brain .*Proc Nat Acad Sci USA* 97:7567-7572.
- Shen IK, James GF, Scanlon MV (2005).** Development of tumor immunogencity and immunotherapy for gliomas. *Nature*; 410:511.
- Shin N H, Hartigan-0 Connor D .Pfeiffer J K ,et al . (2003)** Replication of length Molony murine ieakaemia'vims genomes is impaired at multiple stages *Jvirol* 74:2694-2702.
- Shinmura K, Gorer PA, Bodey B.(2005)** Genetics of cancer. *Nature* 1903; 23:28

-Short, M. P., Choi, B. C., Lee, J. K., Malick, A., Breakefield, X. O. and Martuza, R. L. (1993) Gene delivery to glioma cells in rat brain by grafting of a retrovirus packing cell line. *Journal of Neuroscience Research* 27:427-433.

-Shuey DJ, McCallus DE and Giordano T. (2002) RNAi: gene-silencing in therapeutic intervention. *Drug Discov Today* 7:1040-1046,

-Sicinski, P., Geng, Y., Ryder-C'ook, A.S., Barnard, E.A., Uarlison, M.G., and Barnard, P.J. (2005) the molecular basis of muscular dystrophy in the mdx mouse: A point mutation *Science* 244, 1578-80.

-Siddique, N.; Sufit, R. and Siddique, T. (1999) Degenerative motor. Sensory and autonomic disorders. In Goetz, C.G. and Pappert. E.J. (eds.) : *Textbook of Clinical Neurology*. 1st ed. W.B. Saunders Co.; PP. 695 - 717.

-Siegal T ,Rubinstein R, Bokstein F et al.(2000) In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in human. *J Neurosurg* 92:599-605.

-Simonato M,Manservigi R, Marconi P, Glorioso ,J (2000) Gene transfer into neurons for molecular analysis of behavior: focus on herpes simplex vector .*Trend Neimosd*23:183-190

-Simpson JR and Isacson O.(1993) Mitochondrial impairment reduces the threshold for in vivo NMDA-mediated neuronal death in the striatum.*Exp Neurol* ,121:57-64.

- Slattery WH, Brackmann DE and Hitselberger W. (1998)** Hearing preservation in neurofibromatosis type 2. *Am J Otol* 19:63- 643.
- Slave 1, Schullcr E, Czech T et al.(1999)** Intrathecal mafosfainide therapy for pediatric brain tumors with meningeal dissemination. *J Neurooncol*; 38:213-218.
- Smith, A. E. (1998)** Viral vectors in gene therapy. *Annual Review of Microbiology* 49: 807-838.
- Smithies (1997)** Animal models of human genetic-diseases *trends genet* 9:112-116.
- Smith K T, Shepherd A J, Boyd J E, and Lees G M (1996)** Gene delivery systems for use in gene therapy: an overview of quality assurance and safety issues, *done 7fe-r,3,190-200*.
- Smith, Byers and Jacqueline Fowler.(2002)** Gene Therapy in the Post-Gelsinger Era. *JONA'S Healthcare Law, Ernies, and Regulation* 4(4): 104-110.
- Snow BJ, Lee CS, Schulzer M, Mak E and Calne DB.(1994)** Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic Parkinsonism. *Ann Neurol* 36:759-764 .
- Snyder, D. S., Wu, Y., Wang, J. L., Rossi, J. J., Swiderski, P., Kaplan, B. E., and Forman, S. J. (1993)** Ribozyme mediated inhibition of BCRABL gene expression in a Philadelphia positive cell line. *Blood* 82: 600-605.

- Snyder, R. O., Miao, C. H., Patijn, G. A., Spratt, S. K., Nagy, D., et al. (1997)** Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. *Nature Genetics* 16: 270-275.
- Solter D.(1996)**Steps Involved in Human Germ line Gene Therapy Protocol .*Nature* 380(6569): 24 .
- Sorehe W. (2003)** who own your DNA? Who will win it ^{r)} *Circulation* 1:67-68.
- Sorelle R (2000)** *Hum Gene Ther. Neruron*; 15:32-38
- Soriano P.(1995)** *Annu Rev Nenrosci* 18:1.
- Srinivas, R. V., Y. V. Venkatachalapathi, Z. Rui, R. J. Owens, K. 1k Gupta, S. K. et al. (1991)** Inhibition of virus-induced cell fusion by apolipoprotein A-I and its amphipathic peptidc analogs. *J. Cell Biochem* 45:224-237.
- Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman .1, Holmes G, et al.(1997)** Randomized controlled trial of CDP571 antibody to tumor necrosis factor- α in Gautier's disease *Lancet* 349:521 .
- Stanley, F. J. (1994)** the aetiology of cerebral palsy. *Early Hum. Dc* 36: 81-88, 1994.
- Stanley FJ, Blair E and Alberman E. (2000)** Cerebral palsies epidemiology and causal pathways. *Clinics in Development Medicine* no. 151 London: Mac Keith Press.

-Steiner, I., Spivack, J. G., Lirette, R. P., Brown, S. M., MacLcan, A. R., Subak-Sharpe, J. H. and Fraser, N. W. (1989) Herpes simplex virus type 1 latency-associated transcripts are evident not evidently not essential for latent infection. EMBO Journal .S 505-511.

-Strachen, R.T. (1999) Long term gene expression and phenotypic correction. Hum Gene ther 1999; 68:1792-1801

-Stratton CVV, Mitchell WM and Sri Ram S. (2000) Does chlamydia pneumoniae play a role in the pathogenesis of multiple sclerosis? J Med Microbiol 49:1 -3.

-Stupp R, Hegi ME. (2006) recent developments in the mangement of malignant glioma. Cline Oncol; 779: 1091-1118.

-Sun WH, Burkholder J K, Sun J, et al. (2001) In vivo gene transfer by gene gun reduces tumor growth in mice .Proc Nat Acad Sci: USA; 92:2889-93.

-Sussman, M. (2002) Duchenne muscular dystrophy. J. Am. Acad. Orthop. Surg.; 10(2): 138-151.

-Tait, D. L., Obermiller, P. S., Redlin-Frazier, S., Jensen, Johnson, D. H. and Holt, J. T. (1997) A phase I trial of retroviral gene therapy in ovarian cancer. Clinical Cancer Research 3: 1959-1968.

-Takeda, S. and Miyagoe-Suzuki, Y. (2004) Gene therapy for muscular dystrophies: current status and future prospects. Bio. Drugs; 15 (10): 635-644

- Tannsjo T. (1998)** Should we Change the human genome .theoretical medicine, 14:231 -247.
- Teva Marion Partners.(2001)** Copaxone glatiramer acetate. Kansas City, MO 64134: Teva Marion Partners.
- Thomas H and Sikora K.(1992)** New therapeutic modalities for cancer. ActaOncol 268:2416-9.
- Thompson and Larry (1993)**The First Kids with New Genes. Time 141(23): 50-53.
- Thomsen LL, Olesen J and Rusell MB.(1998)** Familial hemiplegic migraine;160:5325-9.
- Thompson JA, (1995)** Expansion of embryonic stem cells in culture PNAS(USA) 92(17): 7844.
- Thormar, H., C. E. Isaacs, H. R. Brown, M. R. Barshatzkv, anil T. Pessolano. (1987)** Inactivation of enveloped viruses and killing of cells by fatty acids and monoglycerides. Antimicrob.Chemother. 31:27-31.
- Toda, M., S. D. Rabkin, H. Kojima, and R. L. Martuza. (1999)** Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum. Gene Ther. 10:385-393.
- Tolozza, E. M., Hunt, K., Swisher, S., McBride, \V., Lau, R;, Pang, 8 and Economou, J. S.(1996)** In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Therapy3, 11-17.

-Tomita N, Higaki J, Morishita R, Kato K, Mikami H, Kaneda Y and Ogihara T (1992) Direct in vivo gene introduction into rat kidney. *Biochem Biophys Res Comm* 186:129-134. **Trinh N.H., Hoblyn J., Mohanty S. and Yaffe K. (2003)** Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: meta-analysis. *JAMA* 289: 210-216.

-Trinh Y, Gorge K, Martin R,(2003) pharmacological treatment and neuropsychiatric and functional outcomes for patients with AD 210: 112-115.

-Troffater JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, et al(1993) A novel moesin-, ezrin-, radixin-like –B gene is a candidate for the neurofibromatosis 2 tumor suppressor. *Cel I* 72:791 -800.

-Tuszynski, M. H., Roberts, J., Senut, M. C., et al (1996) Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. *Gene Therapy*, 4, 304-314.

-Tuszynski M.H.(2005) Growth-factor gene therapy for neurodegenerative disorders. *Lancet Neurol* 1: 51-57.

-United States Congress.(2000) Senate. Committee on Health, Gene Therapy: Is There Oversight for Patient Safety Public Hearing. Washington, D.C.: Unpublished testimonies and documents from the hearing, 69.

-Van der Meche FG and Schmitz PI(1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. Med (17): 1123-9.

-Verma, I. M. and Somia, N. (1997) Gene therapy - promises, problems and prospects. Nature 389: 239-242.

-Vincent, K. A, PirainO, S; T. and Wadsworth, S. C. (1997) Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products. Journal of Virology 71: 1897-1905.

-Vogel, S. R, (1997) Pathogenesis of human and drug targeting. Biochim Biophys Acta; 1695:3-12

-Waite LM, Broe GA, Creasey H, et al.(1996) Neurological signs, aging, and the neurodegenerative syndromes. Archs Neurol 53:498-502.

-Waldman AS.(1998) Crit Rev Oncol Heftatol 12(1): 49 .

-Walkley, S. U., Wurzelmann, S., Rattazzi, M. C. and Baker, H. J. (1990) Distribution of ectopic neurite growth and. Other geometrical distortions of CNS neurons in feline Gm2-gangliosidosis. Brain Research 510:63-73.

-Walsh, C. I., Liu, J. M., Xiao, X., Young, N. S., and Nienhuis, A. W. (1994) Regulated high level expression of a human γ -globin gene introduced into erythroid cells by an adeno-associated virus vector. *Proceedings of the National Academy of Science USA* 89:7257-7261.

-Walton JN.(1994) Muscular dystrophy: some recent advances in knowledge. *BM.J* i: 1271-1274.

-Walton JN and Nattrass FJ.(1995) On the classification, natural history and treatment of the myopathies. *Brain* 77:169-231.

-Wang, S. and Vos, J. (1996) A hybrid herpes virus infectious vector based on Epstein Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo. *Journal of Virology* 70: 8422-8430.

-Warrick, J. M., H. L. Paulson, G. L. Gray-Bord, Q. T. Bui, and K. H. Fischbein et al., (1998) Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in *Drosophila*. *Cell* 93:939-949.

-Waxman SG (2000) Multiple sclerosis as a neuronal disease. *Archs Neurol* 57:22-24.

-Weggen S., Eriksen J.L., Das P., Sagi S.A., Wing R., Pietrzik C.U et al. (2001) A subset of NSAIDs lower amyloidogenic A β 42 independently of cyclooxygenase activity. *Nature* 414: 212- 216.

-Weiner HL, Gurtman CR, Khoury SJ, et al.(2000) Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability and disease stage. .1 Neuroimmunol 104:164- 173.

-Weinshenker BG. (1995) the natural history of multiple sclerosis. Neurologic clinics 13:119-146.

-Wheeler, C. J., Felgner, P. L., Tsai, Y. J., Marshall, J., Sukhu, L., Soeun, G. H., et al. (1996) A novel cationic lipid greatly enhances plasmid delivery and expression in mouse lung. Proceedings of the National Academy of Sciences USA 93: 11454-11459.

-Wickham, T. J., Mathias, P., Cheresch, D. A., and Nemerow, G. R. (1993) Integrins avb3 and avb5 promote adenovirus internalization but not virus attachment. Cell 73:309-319.

-Wiener CJ.,(2000) Susceptibility to multiple sclerosis: relation between genes and environment. Curr Opin Neurol 13:241-247.

-Wills, K. N., Maneval, D. C., Menzel, P., Harris, M. P., Sutjipto, S., et al (1999). Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Human Gene Therapy5, 1079-1088.

-Wilson JM, Gendicine KL, (2005) Recent development in human genome project Med;334: 1185-1187.

-Wilson JM, Jefferson DM, Chowdhury JR, Novikoff PM, Johnston DE and Mulligan RC (2000) Retrovirus-mediated transduction of adult hepatocytes. Proc Natl Acad Sci USA 85:3014-3018.

-Winblad B.and Poritis N. (1999) Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). *Geriatr Psychiatry* 14: 135-146.

-Winn, S. R., Tresco, P. A., Zielinski, B., Greene, L. A., Jaeger, C. B. and Aebischer, P. (1991) Behavioral recovery following intrastriatal implantations of microencapsulated PC 12 cells *Experimental Neurology* 113:322-329.

- Wivel NA and Walters L (1993) Germ-line gene modification and disease prevention: some medical and ethical perspectives *Science* 262:533-538.

-Wolfe, J. H., Deshmane, S., E.and Fraser, N. W. (1999) Herpes virus vector gene transfer and expression of -glucuronidase in the central nervous system of MPS VII mice. *Nature Genetics* 1:379-384.

-Wolff, J. A., Fisher, L. J., Xu, L., Jinnah, H. A., Langlais, P. J. and Gage, F. H. (1989) Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease. *Proceedings of the National Academy of Science USA* 86:9011-9014.

-Wolff, J,A. and lederberg (2004)An early history of gene transfer and therapy. *Hum Gene Ther* 5:469-480.

-Wolff, J.A.; Malone, R.W.; Williams, P.; et al. (1990) direct gene transfer into mouse muscle in vivo. *Science*; 247: 1465 - 1468.

-Wood, M. J. A., Byrnes, A. P., Pfaff, D. W., Rabkin, S. D. and Charlton, H. M. (1994) Inflammatory effects of gene-transfer into the CNS with defective HSV-1 vectors. *Gene Therapy* 1: 283-291.

-Woolf AS, Bosch RJ and Fine LG (1998) Gene transfer into the mammalian kidney: micro transplantation of retrovirus- transduced metanephric tissue. *Exp Nephrol* 1: 41-48.

-Worgall, S., Wolff, G., Falck-Pedersen, E. and Crystal R. G. (1997) innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. *Human Gene Therapy* 8: 37-44.

-Wygoda, M. R., Wilson, M. R., Davis, M. A., Trosko, J; E., Rehemtulla, A. and Lawrence, T. S. (1997) Protection of herpes simplex virus thymidine kinase-transduced cells from ganciclovir-mediated cytotoxicity: the good Samaritan effect. *Cancer Research* 57: 1699-1703.

-Xiao, X., Li, J. and Samulski, R., 1. (1998). Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. *Journal of Virology* 72:2224-2232. Yanez RJ and Porter AC (1998) Therapeutic gene targeting. *Gene Ther*; 5:149-159.

-Yang, Y. and Wilson, J. M. (1995) Clearance of adenovirus-infected hepatocytes by MHC class 1 restricted CD4+ CTLs in vivo *Journal of Immunology* 155: 2564-2569.

- Yannelli, J., Hyatt, C. , Johnston, S., Hwu, P. and Rosenberg, S. (1993)** Characterization of human tumor cell lines transduced with the cDNA encoding either tumor necrosis factor α or interleukin2 (IL2). Journal of Immunological Methods 161: 77- 90.
- Yanez K, Porter NM, (1998)** *aims* of human gene therapy protocols. Hum Gene Ther; 8:112-115
- Yates JL .warren N. Sugden B (1995)** .Stable replication of plasmids derived from Epstein Barr Virus in various mammalian cells .nature :313:812-5.
- Yoon, S., E. A. Chiocca, and K. Tanabe.(2000).** Treatment of multiple liver metastases by intravascular delivery of an Oncolytic HSV FASEBJ. 14:301-311.
- Young SW, Qing F, Harriman A et al.(1996)** Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc Natl Acad Sci USA 93:6610-6615.
- Zaiss, A.K., Liu, Q., Bowen, G.P., Wong, N.C., Bartlett, J.S. and Muruve, D.A. (2002)** Differential activation of innate immune responses of adenovirus and adeno-associated virus vectors. J. Virol., 76, 4580-4590.
- Zeitlin P L (2003)** Cystic fibrosis gene therapy trials and tribulations. Mol ther 1:5-6.

-Zelcnin AV, Kolesnikov V. Tarasenko OA, Shafiei RA, Zeicninn IA, Mikhailov VV and Baranovand VS (1997) Bacterial beta-galactosidase and human dystrophin genes are expressed in mouse skeletal muscle fibers after ballistic transfection. FEBS Letters 414:319-322.

-Zhu G, Nicolson AG, Zheng XX, Strom TB and Sukhatme VP (1997) Adenovirus-mediated beta-galactosidase gene delivery to the liver leads to protein deposition in kidney glomeruli. Kidney 52:992-999.